Gland Pharma Gets Listed Today: All Eyes on the Fast-growing B2B Company

Gland Pharma is expected to list at 10 percent or above premium to issue price, said an expert. Backed by Chinese company Fosun Pharma, the firm registered a profit growth at a 55.2 percent CAGR and revenue at 27.4 percent CAGR, while EBITDA grew at a 33.6 percent CAGR during FY18-FY20.

from Top Business News- News18.com https://ift.tt/3fk0cGO